398 related articles for article (PubMed ID: 17592509)
21. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM
Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811
[TBL] [Abstract][Full Text] [Related]
22. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.
Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB
Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240
[TBL] [Abstract][Full Text] [Related]
23. Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation.
Tallett AJ; Blundell JE; Rodgers JR
Behav Pharmacol; 2007 Nov; 18(7):591-600. PubMed ID: 17912043
[TBL] [Abstract][Full Text] [Related]
24. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.
Savinainen JR; Saario SM; Niemi R; Järvinen T; Laitinen JT
Br J Pharmacol; 2003 Dec; 140(8):1451-9. PubMed ID: 14623770
[TBL] [Abstract][Full Text] [Related]
25. Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor.
Bertini S; Chicca A; Gado F; Arena C; Nieri D; Digiacomo M; Saccomanni G; Zhao P; Abood ME; Macchia M; Gertsch J; Manera C
Bioorg Med Chem; 2017 Dec; 25(24):6427-6434. PubMed ID: 29079014
[TBL] [Abstract][Full Text] [Related]
26. Allosteric modulation of the cannabinoid CB1 receptor.
Price MR; Baillie GL; Thomas A; Stevenson LA; Easson M; Goodwin R; McLean A; McIntosh L; Goodwin G; Walker G; Westwood P; Marrs J; Thomson F; Cowley P; Christopoulos A; Pertwee RG; Ross RA
Mol Pharmacol; 2005 Nov; 68(5):1484-95. PubMed ID: 16113085
[TBL] [Abstract][Full Text] [Related]
27. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569.
Gamage TF; Ignatowska-Jankowska BM; Wiley JL; Abdelrahman M; Trembleau L; Greig IR; Thakur GA; Tichkule R; Poklis J; Ross RA; Pertwee RG; Lichtman AH
Behav Pharmacol; 2014 Apr; 25(2):182-5. PubMed ID: 24603340
[TBL] [Abstract][Full Text] [Related]
28. Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats.
Drew LJ; Harris J; Millns PJ; Kendall DA; Chapman V
Eur J Neurosci; 2000 Jun; 12(6):2079-86. PubMed ID: 10886347
[TBL] [Abstract][Full Text] [Related]
29. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
[TBL] [Abstract][Full Text] [Related]
30. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG
Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977
[TBL] [Abstract][Full Text] [Related]
31. Reciprocal inhibition of G-protein signaling is induced by CB(1) cannabinoid and GABA(B) receptor interactions in rat hippocampal membranes.
Cinar R; Freund TF; Katona I; Mackie K; Szucs M
Neurochem Int; 2008 Jun; 52(8):1402-9. PubMed ID: 18407377
[TBL] [Abstract][Full Text] [Related]
32. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
[TBL] [Abstract][Full Text] [Related]
33. Benzophenanthridine alkaloid, piperonyl butoxide and (S)-methoprene action at the cannabinoid-1 receptor (CB1-receptor) pathway of mouse brain: Interference with [(3)H]CP55940 and [(3)H]SR141716A binding and modification of WIN55212-2-dependent inhibition of synaptosomal l-glutamate release.
Dhopeshwarkar AS; Nicholson RA
Eur J Pharmacol; 2014 Jan; 723():431-41. PubMed ID: 24211785
[TBL] [Abstract][Full Text] [Related]
34. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.
Cluny NL; Vemuri VK; Chambers AP; Limebeer CL; Bedard H; Wood JT; Lutz B; Zimmer A; Parker LA; Makriyannis A; Sharkey KA
Br J Pharmacol; 2010 Oct; 161(3):629-42. PubMed ID: 20880401
[TBL] [Abstract][Full Text] [Related]
35. Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats.
Ward SJ; Lefever TW; Rawls SM; Whiteside GT; Walker EA
Psychopharmacology (Berl); 2009 Sep; 206(1):155-65. PubMed ID: 19575185
[TBL] [Abstract][Full Text] [Related]
36. Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist.
Hadcock JR; Carpino PA; Iredale PA; Dow RL; Gautreau D; Thiede L; Kelly-Sullivan D; Lizano JS; Liu X; Van Deusen J; Ward KM; O'Connor RE; Black SC; Griffith DA; Scott DO
BMC Pharmacol; 2010 Aug; 10():9. PubMed ID: 20712891
[TBL] [Abstract][Full Text] [Related]
37. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity.
Zádor F; Kocsis D; Borsodi A; Benyhe S
Neurochem Int; 2014 Feb; 67():14-22. PubMed ID: 24508403
[TBL] [Abstract][Full Text] [Related]
38. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.
Ahn KH; Mahmoud MM; Kendall DA
J Biol Chem; 2012 Apr; 287(15):12070-82. PubMed ID: 22343625
[TBL] [Abstract][Full Text] [Related]
39. Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1.
Fay JF; Farrens DL
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8469-74. PubMed ID: 26100912
[TBL] [Abstract][Full Text] [Related]
40. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
Serrano A; Del Arco I; Javier Pavón F; Macías M; Perez-Valero V; Rodríguez de Fonseca F
Neuropharmacology; 2008 Jan; 54(1):226-34. PubMed ID: 17467748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
